China
Juventas Cell Therapy Corp., founded in 2018, is a pioneering biotechnology firm based in China that specializes in the research and commercialization of innovative immune cell therapies. The company collaborates extensively with top-tier national institutions and clinical research centers to create a leading platform for clinical translation and commercialization of cell therapy.
Their flagship immunotherapy product, the CNCT19 Cell Injection, holds Chinese proprietary rights and has received clinical trial approvals from the National Medical Products Administration for treating refractory or relapsed acute lymphoblastic leukemia and aggressive B-cell non-Hodgkin lymphomas. This positions Juventus to serve China's hematologic oncology patients swiftly.
In July 2021, the company secured a CNY410.00M Series C investment from a prominent group of investors including Delian Capital, CICC, Dalton Venture, Ding Xiang Capital, Redhill Capital, Jiadao Capital, and Haisong Capital, demonstrating strong investor confidence in its expansive, competitive, and globally-relevant drug pipeline.
